Related Experiment Videos
Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer
Abstract:
Seventeen patients with advanced progressive prostatic cancer who had relapsed or failed to respond to conventional endocrine therapy with oestrogens, orchiectomy or antiandrogens were treated with the LHRH analogue, ICI 118630. No significant objective tumour responses were seen, though 11 of 15 patients who presented with symptomatic metastatic bone pain had rapid short-term pain relief. The lack of objective clinical response seen in this study indicates no justification for the use of LHRH analogues in this group of patients. Though a significant subjective response was seen there was no added advantage over regular analgesics.
Insights
This study found that LHRH analogues did not significantly shrink tumors in advanced prostate cancer patients. While some patients experienced short-term pain relief, it offered no advantage over standard pain medication.
Area of Science:
- Oncology
- Endocrinology
Background:
- Advanced prostate cancer often becomes resistant to conventional endocrine therapies.
- Luteinizing hormone-releasing hormone (LHRH) analogues are used in prostate cancer treatment.
- Investigating novel therapeutic options for treatment-resistant prostate cancer is crucial.
Purpose of the Study:
- To evaluate the efficacy of the LHRH analogue ICI 118630 in patients with advanced progressive prostate cancer.
- To assess objective tumor response and subjective pain relief in patients refractory to standard endocrine therapy.
Main Methods:
- Seventeen patients with advanced, progressive prostate cancer were treated with the LHRH analogue ICI 118630.
- Patients had previously failed or relapsed after conventional endocrine treatments (oestrogens, orchiectomy, antiandrogens).
- Tumor response and pain levels were monitored.
Main Results:
- No significant objective tumor responses were observed in any patients.
- Eleven out of fifteen patients with metastatic bone pain reported rapid, short-term pain relief.
- Subjective pain relief did not demonstrate an added advantage over regular analgesics.
Conclusions:
- LHRH analogues like ICI 118630 do not show efficacy in achieving objective tumor responses in advanced prostate cancer patients resistant to standard endocrine therapy.
- While short-term pain relief was noted, it does not justify the use of LHRH analogues over conventional pain management.
- Further research may be needed to explore alternative treatments for refractory prostate cancer.